Lund — 9 January 2017 — Camurus AB (Nasdaq Stockholm; CAMX) today announces that that the Company will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, at 11:30 am Pacific time on January 12, 2017. Fredrik Tiberg, President and CEO, will provide a company overview including an update on the progress of the development pipeline.
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit www.camurus.com.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
Rein Piir, VP Investor Relations
Tel. +46 (0)70 853 72 92
The information was submitted for publication at 08.00 a.m. on 9 January 2017.